UNSPSC 51312305: Embramine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H22BrNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HH0KD7Z416, chemically known as 2-(p-bromo-alpha-methyl-alpha-phenylbenzyloxy)-n,n-dimethylethyl amine but generally known as embramine, which bears US NIH Compound Identifier 19105. European Medicines Agency schedules Embramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06500MIG. The term EMBRAMINE is an International Non-Proprietary Name.

UNSPSC 51312305 Embramine, a Commodity code, appears in state and local procurement primarily for naloxone products and related drug-safety systems, though the recent solicitations tagged under this code diverge significantly from the nominal category. The work being solicited includes naloxone procurement for community health initiatives, therapeutic pharmacy programs, and multi-state generic pharmaceutical distribution — spanning emergency overdose-response supplies, pharmacy benefit program management, and OTC product sourcing. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The code shows limited recent activity; only three opportunities posted between January and June 2026 appear in the block, suggesting modest ongoing demand for these product categories among state and local buyers.

Recent solicitations span Florida, Texas, and Minnesota. Seminole County's IFB 60459723LAS (due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capability information on direct-to-manufacturer prescription programs for self-insured health plans, signaling early-stage procurement design rather than formal solicitation. Minnesota's MMCAP released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), with awards effective July 1, 2026 and evaluation weighted heavily on price competitiveness (75 percent). The MMCAP contract includes a 3 percent administrative fee, cGMP and DSCSA compliance requirements, and extends through June 30, 2028 for incumbent responders.